Intellia宣佈使用其專有的Lnp-Based交付平台重新注射CRISPR基因編輯治療

快訊 · 06/26 03:30

Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy With Its Proprietary Lnp-Based Delivery Platform

Intellia宣佈使用其專有的Lnp-Based交付平台重新注射CRISPR基因編輯治療的積極臨床概念驗證數據。